{"name":"Aclipse Two Inc.","slug":"aclipse-two-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPb1UwZ0VRbkhadFl5U0hLUVk2d0c1d2hPU0Y0NGp0UU1KNUxLQ3AyRnM1VWdkbUtHWnNJX09UbFdpcHhhUEdmS09SbmZ0c05ZZXozcURlZE9OUmQ4cERaNlNVSHZ1Y3o1TTBDOVF5akxxRlVqNjVpUWR3dHo3WHZlYVpvVkVuNzN1N3lobjhsU3BxeUtFVFB3Tk5NY1BHNlFqOEdub3UxXy03SXhsU0dLNTZ4Y2xJQUdlczhKZG9vVTBBQXlkaGRRWFZxQ0RBaXRzNS13a014WlFILVZPdTB1Umc2N0M2bC1vZW90WXctbWJsVTE2U1lFSzlIakpqYUVxbDdRNFdYNVdfOENuNXpTYlh3?oc=5","date":"2025-11-17","type":"trial","source":"businesswire.com","summary":"Aclipse Therapeutics to Collaborate with Mayo Clinic on Phase 2 Clinical Development of M107 for the Treatment of Gastroparesis - businesswire.com","headline":"Aclipse Therapeutics to Collaborate with Mayo Clinic on Phase 2 Clinical Development of M107 for the Treatment of Gastro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPWXRudks4Nkc1cFk4bS1nR0o4T0NjX3lhNGRfWVkxdVljSFM2MTY0VmM4Z2xVRk5USEdtcG1udkk3Tm11cnhyRV9YSTFoVExnUkxLSV9pME9PWXV4ZE5Kc3RuNXRua19sQTlMTVNILTdqdTFyWkwtMTVXTHdnM24zcjExYmtBUzNmQkZuZXUwSHdaQThhYVdsejdUX1I5MEFtN2xkWjc1QW9iU0pKQjVzV2FOX0Y4VmZFR3haWk9qVzMyelBRYTJhTHVjVWVmdWhiN2dON2ZRSFJvNkRJOHprY3pleWhWVXk3SGh0bXFHS3pOMU5wakswTzBjamxrUzI5amlNSlc2SkkyTlMtcXZVTXgzR2JZNW1H?oc=5","date":"2024-11-07","type":"pipeline","source":"businesswire.com","summary":"Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia - businesswire.com","headline":"Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Dise","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}